Artificial Blood: Current Status, Development, and Future Prospects

---

Artificial blood, often referred to as oxygen carriers, is engineered to perform the core function of red blood cells—transporting oxygen to tissues and removing carbon dioxide—while excluding the clotting and immune‑support roles of whole blood.

Background

Blood is a specialized connective tissue composed of plasma, white blood cells, platelets, and red blood cells. Plasma, a watery matrix rich in proteins, salts, and clot‑forming factors, keeps blood fluid and aids hemostasis. White cells protect the body from pathogens, while platelets seal vascular injury. Red cells, identifiable by their hemoglobin‑rich cytoplasm, provide the striking red hue and serve as the primary oxygen transport system.

Modern artificial blood focuses exclusively on red‑cell function. Because these products lack cellular membranes, they are not subject to blood‑typing constraints, a key advantage over conventional transfusion.

History

The quest for blood substitutes dates back to the early 17th century, when William Harvey’s 1616 description of systemic circulation sparked attempts to replace blood with various fluids—beer, urine, milk, and animal plasma. Although early trials, including the 1667 first human transfusion, were marred by fatal reactions, they laid the groundwork for systematic research.

In 1854 milk was briefly trialed as a cholera treatment, but skepticism and lack of reproducible benefit ended its use. The 1883 invention of Ringer’s solution demonstrated that a saline mix could restore blood pressure after volume loss, eventually evolving into a clinically useful plasma volume expander, though it does not substitute for red‑cell oxygen delivery.

Landsteiner’s 1901 discovery of the ABO blood‑group system revolutionized transfusion safety. By separating serum from cells and observing clotting patterns, he classified human blood into A, B, AB, and O groups—a breakthrough that earned him the 1930 Nobel Prize in Physiology or Medicine.

World War I and II spurred research into plasma substitutes and the first perfluorochemical (PFC) trials. PFCs, long‑chain fluorinated polymers, can dissolve up to 50 times more oxygen than plasma. Early animal studies in 1966‑68 showed that mice and rats survived after their blood was replaced with PFC emulsions, hinting at a potential non‑blood oxygen carrier.

Despite the promise of PFCs, the robustness of the U.S. blood‑bank system kept the focus on donated blood until the Vietnam War exposed supply vulnerabilities and the 1986 AIDS crisis highlighted transfusion‑borne pathogen risks. These events renewed interest in hemoglobin‑based and synthetic oxygen carriers.

Design Criteria

An ideal artificial blood must:

• Be universally compatible, independent of donor‑recipient blood type.
• Contain no infectious agents; all viruses and bacteria must be removed or inactivated.
• Transport oxygen efficiently and release it where needed.
• Be shelf‑stable for at least one year, surpassing the 30‑day limit of refrigerated human blood.
• Include mechanisms for other physiological functions (e.g., buffering capacity), though this remains a long‑term goal.

Current Development Platforms

Perfluorocarbons (PFC)

PFCs are chemically inert and can dissolve large volumes of dissolved gases. They are produced without biological components, eliminating infection risk. Key challenges are their poor water solubility—necessitating lipid emulsifiers—and their relatively low oxygen payload compared to hemoglobin. An FDA‑approved PFC product exists but commercial uptake has been limited by the high volume required to achieve therapeutic effect. Ongoing research focuses on more stable, higher‑capacity emulsions.

Hemoglobin‑Based Products

Hemoglobin‑based oxygen carriers (HBOCs) exploit the natural oxygen‑binding properties of hemoglobin. Because they lack a cell membrane, ABO incompatibility is not an issue. However, free hemoglobin is rapidly oxidized and can cause vasoconstriction and oxidative stress. Solutions include chemical cross‑linking, polymerization, or recombinant production of modified hemoglobin. Current strategies involve:

• Isolation of human hemoglobin from expired donations or animal plasma, followed by detoxification and stabilization.
• Recombinant hemoglobin expressed in engineered E. coli strains, allowing large‑scale production with precise modifications.
• Use of cross‑linkers or recombinant DNA techniques to enhance stability, reduce nephrotoxicity, and improve oxygen affinity.

These products promise higher oxygen capacity and longer circulation times, with several candidates in Phase II clinical trials.

Raw Materials

Depending on the platform, key inputs include:

• Hemoglobin‑based HBOCs: isolated human or animal hemoglobin, recombinant hemoglobin synthesized from amino acids, fermentation media (warm water, glucose, molasses, vitamins, urea, liquid ammonia), and cross‑linking agents.
• PFC emulsions: perfluorinated compounds, phospholipid emulsifiers, and stabilizers.

Manufacturing Process

The production pipeline varies by platform, but for recombinant hemoglobin it typically follows these steps:

Hemoglobin Synthesis

1. Inoculate an engineered E. coli strain capable of producing human hemoglobin into a small culture vessel with growth media.
2. Expand the culture in a stainless‑steel seed tank under controlled temperature, pH, and aeration to build biomass.
3. Transfer the biomass to a larger fermentation tank, maintaining optimal conditions to maximize hemoglobin yield.
4. Harvest the culture; use centrifugation and chromatographic separation to isolate hemoglobin.
5. Purify the protein through fractional distillation or column chromatography, ensuring removal of endotoxins and contaminants.

Final Processing

• Combine purified hemoglobin with electrolytes and buffering agents to create a physiologically compatible solution.
• Pasteurize the final product to eradicate residual microbes.
• Perform rigorous quality control—pH, osmolarity, endotoxin levels, hemoglobin integrity—before filling into sterile vials or bags.
• Label and store at recommended temperatures; batches up to 10,000 L (2,640 gal) have been produced in pilot facilities.

Future Outlook

Current HBOCs have a limited in‑body half‑life of 20–30 hours versus 34 days for whole blood, and they lack clotting and immune functions. Consequently, their present clinical role is confined to short‑term emergency resuscitation. Research priorities include:

• Developing longer‑acting formulations that match the durability of natural red cells.
• Engineering carriers that can mimic additional blood functions, such as coagulation support and immune modulation.
• Scaling production to meet projected U.S. annual demand of over $7.6 billion once a commercially viable product is available.

As regulatory frameworks tighten and manufacturing technologies mature, the next decade may bring the first truly safe, effective artificial blood to market—transforming trauma care, surgical practice, and global transfusion logistics.